<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02261116</url>
  </required_header>
  <id_info>
    <org_study_id>502.402</org_study_id>
    <nct_id>NCT02261116</nct_id>
  </id_info>
  <brief_title>Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers</brief_title>
  <official_title>Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess potential different properties of telmisartan, which due to its Vd, should
      result in stronger &quot;beneficial&quot; effects of AT1 blockade in tissues (e.g. aldosterone
      suppression and renin increase) plus stronger AT2 stimulation compared to candesartan
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slope of PRA increase versus DR-1</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
    <description>analysis of variance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of angiotensin-1 (AT1) pressor antagonism in vivo (DR-1)</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
    <description>rightward shift (DR-1) of diastolic blood pressure response to Angiotensin II dose escalating challenges</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma aldosterone concentration after stimulation with Angiotensin II</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive response of the plasma renin activity (PRA)</measure>
    <time_frame>Predose and 2, 4, 8 h following trial medication</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>Micardis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <arm_group_label>Candesartan</arm_group_label>
    <other_name>Blopress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males, aged 18 to 45 years.

          2. Absence of any relevant disease as determined by no clinically deviation from normal
             in medical history, clinical laboratory determination, ECGs and physical examinations

          3. Systolic blood pressure (SBP) between 100 and 140 mmHg systolic and below 85 mmHg
             diastolic (both left and right arm) and a heart rate of ≥50 bpm

          4. Signed informed consent form

          5. No intake of drugs inbetween a waiting time of ten times of half-life

        Exclusion Criteria:

          1. Contraindications to Ang II antagonists, known hypersensitivity, history of
             angioedema, serious allergy, asthma, allergic skin rash, significant allergic rhinitis
             or sensitivity to any drug

          2. History of cardiovascular diseases: any clinically significant cardio-vascular
             disease, a supine diastolic blood pressure &gt;86 mmHg and systolic &gt;141 mmHg measured by
             a standard sphygmomanometer or a heart rate ≤49 bpm

          3. Cerebrovascular diseases: history of stroke or transitory ischemic attacks (TIAs) or
             history of any cerebral bleeding

          4. Renal diseases: serum creatinine &gt;1.5 mg/dL

          5. Gastrointestinal/Hepatic diseases: Aspartate aminotransferase (ASAT) &gt;40 U/l or
             Alanine aminotransferase (ALAT) &gt;40 U/L, serum bilirubin &gt;2x upper limit of normal,
             history of malabsorption or inability to tolerate oral medication, history of gastric
             or duodenal ulcers, history of significant gastrointestinal bleeding, history of
             hepatitis within the past years

          6. Any history of alcohol or drug abuse

          7. Use of any of the following drugs within 4 weeks of study enrolment (e.g. agents known
             to induce drug metabolizing enzymes): anabolic steroids and corticoids,
             antiarrhythmics (amiodarone, mexiletine, quinidine, propafenone), antibiotics
             (chloramphenicol, tetracyclines, sulfonamides, macrolides, cephalosporins, rifampicin,
             nalidixic acid), antiepileptics (phenytoin, carbamazepine), antifungals (e.g.
             griseofulvin), barbiturates, cimetidine, ethacrynic acid, fibrates, furosemide,
             haloperidol, lipid lowering agents (cholestyramine, hydroxymethylglutaryl, coenzyme A
             (HMG CoA) reductase inhibitors, dextrothyroxin), thyroid replacement therapy hormones
             or thyrostatics (thioureylene-type). The use of nonsteroidal antiinflammatory drugs
             (NSAIDs) should be discontinued 2 weeks prior to study enrolment, the one exception of
             aspirin should be one (1) week prior to study enrolment

          8. Participation in any other investigational study, within the 30 days prior to
             enrolment

          9. Blood donation within the previous 3 months

         10. The investigator might disqualify a subject for a sound medical or psychiatric reason
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2014</study_first_submitted>
  <study_first_submitted_qc>October 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2014</study_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

